US 10660904
Optimizing mifepristone levels for cushing's patients
granted A61KA61K31/122A61K31/135
Quick answer
US patent 10660904 (Optimizing mifepristone levels for cushing's patients) held by Corcept Therapeutics Incorporated expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/122, A61K31/135, A61K31/136, A61K31/567